Source briefing
Human medicines European public assessment report (EPAR): Tolvaptan Accord, tolvaptan, Revision: 2, Status: Authorised
Human medicines European public assessment report (EPAR): Tolvaptan Accord, tolvaptan, Revision: 2, Status: Authorised
Read →
Source briefing
Human medicines European public assessment report (EPAR): Suboxone, buprenorphine,naloxone, Date of authorisation: 26/09/2006, Revision: 24, Status: Withdrawn
Human medicines European public assessment report (EPAR): Suboxone, buprenorphine,naloxone, Date of authorisation: 26/09/2006, Revision: 24, Status: Withdrawn
Read →
Source briefing
Encampment sweeps and persistent homelessness among unhoused people who use drugs in Vancouver, Canada: A prospective cohort study
by Kanna Hayashi, Eric C. Sayre, Jennifer McDermid, Samona Marsh, Caitlin Shane, Michael-John Sheridan Milloy, P.O.W.E.R. , Thomas Kerr Background Housing is a key determinant of health. In response to increasingly visible homelessness amid a growing housing crisis,…
Read →Source briefing
Human medicines European public assessment report (EPAR): Nezglyal, leriglitazone, Date of authorisation: 21/09/2026, Status: Authorised
Human medicines European public assessment report (EPAR): Nezglyal, leriglitazone, Date of authorisation: 21/09/2026, Status: Authorised
Read →Source briefing
Human medicines European public assessment report (EPAR): Ruxolitinib Viatris, ruxolitinib hemifumarate, Date of authorisation: 18/09/2026, Status: Authorised
Human medicines European public assessment report (EPAR): Ruxolitinib Viatris, ruxolitinib hemifumarate, Date of authorisation: 18/09/2026, Status: Authorised
Read →Source briefing
Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 18, Status: Authorised
Human medicines European public assessment report (EPAR): Tevimbra, tislelizumab, Date of authorisation: 15/09/2023, Revision: 18, Status: Authorised
Read →Source briefing
Human medicines European public assessment report (EPAR): Pregabalin Viatris Pharma (previously Pregabalin Pfizer), pregabalin, Date of authorisation: 10/04/2014, Revision: 39, Status: Authorised
Human medicines European public assessment report (EPAR): Pregabalin Viatris Pharma (previously Pregabalin Pfizer), pregabalin, Date of authorisation: 10/04/2014, Revision: 39, Status: Authorised
Read →Source briefing
Human medicines European public assessment report (EPAR): Susvimo, ranibizumab, Date of authorisation: 18/09/2026, Status: Authorised
Human medicines European public assessment report (EPAR): Susvimo, ranibizumab, Date of authorisation: 18/09/2026, Status: Authorised
Read →Source briefing
European standards of prevention and care: Module on antenatal screening for HIV, hepatitis B and syphilis
The global community has committed to eliminating vertical transmission of HIV, hepatitis B virus (HBV) and syphilis as a public health priority. This global commitment encourages countries to provide the most effective, high-quality and person-centred care available to…
Read →Source briefing
Evaluation of the tuberculosis notification impact from an intermediary-facilitated public–private mix intervention in Viet Nam: A population-level quasi-experimental study
by Luan Nguyen Quang Vo, Thuy Thi Thu Dong, Huy Ba Huynh, Binh Anh Luong, Huong Thi Lan Mo, Andrew James Codlin, Rachel Forse, Thuy Doan To Mai, Lan Phuong Nguyen, Jacob Creswell, Luong Van Dinh, Hoa Binh…
Read →